Publication: Prospective research on infants with mild encephalopathy: The PRIME study
Issued Date
2018-01-01
Resource Type
ISSN
14765543
07438346
07438346
Other identifier(s)
2-s2.0-85040818903
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Journal of Perinatology. Vol.38, No.1 (2018), 80-85
Suggested Citation
C. Prempunpong, L. F. Chalak, J. Garfinkle, B. Shah, V. Kalra, N. Rollins, R. Boyle, K. A. Nguyen, I. Mir, A. Pappas, P. Montaldo, S. Thayyil, P. J. Sánchez, S. Shankaran, A. R. Laptook, G. Sant'anna Prospective research on infants with mild encephalopathy: The PRIME study. Journal of Perinatology. Vol.38, No.1 (2018), 80-85. doi:10.1038/jp.2017.164 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/47234
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Prospective research on infants with mild encephalopathy: The PRIME study
Abstract
© 2018 Nature America, Inc., part of Springer Nature. All rights reserved. Objective:To determine short-term outcomes of infants with evidence of hypoxia-ischemia at birth and classified as mild neonatal encephalopathy (NE) at <6 h of age.Study Design:Prospective multicenter study. Mild NE was defined as 3/41 abnormal category in modified Sarnat score. Primary outcome was any abnormality on early amplitude integrated electroencephalogram (aEEG) or seizures, abnormal brain magnetic resonance imaging (MRI) or neurological exam at discharge.Results:A total of 54/63 (86%) of enrolled infants had data on components of the primary outcome, which was abnormal in 28/54 (52%): discontinuous aEEG (n=4), MRI (n=9) and discharge exam (n=22). Abnormal tone and/or incomplete Moro were the most common findings. MRI abnormalities were confined to cerebral cortex but two infants had basal ganglia and/or thalamus involvement. The 18 to 24 months follow-up is ongoing.Conclusions:A larger than expected proportion of mild NE infants with abnormal outcomes was observed. Future research should evaluate safety and efficacy of neuroprotection for mild NE.